8-K: bioAffinity Technologies Secures Key Lung Cancer Diagnostic Patent in China

bioAffinity Technologies, Inc. announced the allowance of a patent application in China for its noninvasive lung cancer diagnostic, CyPath Lung, positioning the company for future opportunities in a significant global healthcare market.

Summary

• bioAffinity Technologies, Inc. received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application.
• The patent, titled 'System and Method for Determining Lung Health,' protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the use of flow cytometry to determine the presence of lung cancer cells in sputum.
• This patent is related to the company's noninvasive lung cancer diagnostic, CyPath Lung, which is commercially available.
• China represents a large prospective market for CyPath Lung, with over 300 million smokers, nearly one-third of the world's total, and an estimated 1.06 million new cases of lung cancer diagnosed in 2022.
• Clinical study results for CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules less than 20 millimeters.
• CyPath Lung detected all forms of lung cancer and 80% of cancers that were Stage 1 in the study.
• The newly allowed Chinese patent complements bioAffinity's expanding global patent estate, which now includes multiple patents in the U.S., China, Japan, Australia, Mexico, Canada, and the EU.

Sentiment

Score: 8

Explanation: The allowance of a key patent in a major market like China for a diagnostic product is a strong positive development for a biotechnology company, indicating progress in market access and intellectual property protection.

Positives

• Securing a patent in China for CyPath Lung opens access to a significant market with over 300 million smokers and 1.06 million new lung cancer cases estimated in 2022.
• The patent strengthens the company's intellectual property portfolio globally, adding to existing patents in the U.S., Japan, Australia, Mexico, Canada, and the EU.
• CyPath Lung has demonstrated strong clinical performance with 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer, including 80% of Stage 1 cancers.

Risks

• The company's ability to derive benefits from the newly allowed patent is subject to various risks and uncertainties.
• Actual results could differ materially from current expectations due to factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

The company anticipates that securing this intellectual property in China will position it well for future opportunities in one of the world's largest and most underserved healthcare markets. It is seen as a step forward in safeguarding and expanding the reach of their proprietary diagnostic platform internationally and building long-term shareholder value.

Management Comments

• Maria Zannes, President and CEO of bioAffinity Technologies, stated: 'This patent is another step forward in our strategy to safeguard and expand the reach of our proprietary diagnostic platform internationally. With lung cancer representing a major health burden globally and particularly in China, we believe that securing this intellectual property positions us well for future opportunities in one of the worlds largest and most underserved healthcare markets. It reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives.'

Industry Context

This announcement relates to the global effort to combat lung cancer, a major health burden, particularly in countries with high smoking rates like China. The development of noninvasive, accurate early-stage diagnostics like CyPath Lung aligns with broader industry trends focusing on improving patient outcomes through earlier detection and less invasive procedures. The expansion into the Chinese market addresses a significant unmet medical need given the country's large smoker population and high incidence of lung cancer.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark CyPath Lung's performance or market potential against industry standards.

Stakeholder Impact

• Shareholders: Potential for long-term shareholder value creation through innovation and expansion into new markets.
• Patients: Improved access to noninvasive early-stage lung cancer detection, potentially leading to better outcomes and increased survival.
• Healthcare System: Addresses a major health burden by providing a tool for early cancer detection in a high-incidence region.

Next Steps

• Continued execution of the strategy to safeguard and expand the reach of the proprietary diagnostic platform internationally.
• Exploration of future opportunities in the Chinese healthcare market for CyPath Lung.

Key Dates

Keywords

lung cancer, diagnostic, patent, China, CyPath Lung, biotechnology, noninvasive, flow cytometry, intellectual property, early detection, sputum, cancer screening